Levosimendan
99%
- Product Code: 74046
CAS:
141505-33-1
Properties:
Solubility: DMSO: ≥20 mg/mL
| Molecular Weight: | 280.28 g./mol | Molecular Formula: | C₁₄H₁₂N₆O |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD00867135 | |
| Melting Point: | 205°C | Boiling Point: | |
| Density: | Storage Condition: | room temperature, dry |
Product Description:
Levosimendan is primarily used in the treatment of acute decompensated heart failure, particularly when conventional therapies are insufficient. It works by enhancing cardiac contractility without significantly increasing oxygen demand, making it beneficial for patients with compromised heart function. The drug is also employed in managing low cardiac output syndrome following cardiac surgery, helping to improve hemodynamic stability. Additionally, Levosimendan has shown potential in treating cardiogenic shock and pulmonary hypertension due to its vasodilatory effects. Its unique mechanism of action, which involves calcium sensitization and opening of potassium channels, makes it a valuable option in critical care settings where immediate improvement in cardiac performance is required.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | Pale yellow - Reddish yellow Crystal - Powder |
| PURITY | 98.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.050 | 10-20 days | $30.67 |
+
-
|
| 0.250 | 10-20 days | $105.00 |
+
-
|
| 1.000 | 10-20 days | $309.10 |
+
-
|
Levosimendan
Levosimendan is primarily used in the treatment of acute decompensated heart failure, particularly when conventional therapies are insufficient. It works by enhancing cardiac contractility without significantly increasing oxygen demand, making it beneficial for patients with compromised heart function. The drug is also employed in managing low cardiac output syndrome following cardiac surgery, helping to improve hemodynamic stability. Additionally, Levosimendan has shown potential in treating cardiogenic shock and pulmonary hypertension due to its vasodilatory effects. Its unique mechanism of action, which involves calcium sensitization and opening of potassium channels, makes it a valuable option in critical care settings where immediate improvement in cardiac performance is required.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
$0.00
$0.00
Total :